Association between programmed cell death ligand 1 expression and thyroid cancer

Wan, Baoyu; Deng, Pengyi; Dai, Wenli; Wang, Peng; Dong, Zhizhi; Yang, Chaojun; Jin-ling, Tian; Hu, Tao; Yan, Kai

doi:10.1097/md.0000000000025315

Cited by 12 publications

(9 citation statements)

References 44 publications

(44 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Several experimental and clinical data suggest that other molecules may have a role in the prognostic stratification of TC patients. These include immune checkpoint factors and immune-related signature (IRS), estrogen receptors, Vitamin D, tumor angiogenic microenvironment, circular RNAs, long noncoding RNAs, and the angiotensin converting enzymes ACE and ACE2 [ 184 , 185 , 186 , 187 , 188 , 189 , 190 , 191 , 192 , 193 , 194 ]. However, all of them are awaiting validation in large case studies.…”

Section: Thyroid Cancer Patient’s Stagingmentioning

confidence: 99%

Papillary Thyroid Cancer Prognosis: An Evolving Field

Ulisse

Baldini

Lauro

et al. 2021

Cancers

View full text Add to dashboard Cite

Over the last few years, a great advance has been made in the comprehension of the molecular pathogenesis underlying thyroid cancer progression, particularly for the papillary thyroid cancer (PTC), which represents the most common thyroid malignancy. Putative cancer driver mutations have been identified in more than 98% of PTC, and a new PTC classification into molecular subtypes has been proposed in order to resolve clinical uncertainties still present in the clinical management of patients. Additionally, the prognostic stratification systems have been profoundly modified over the last decade, with a view to refine patients’ staging and being able to choose a clinical approach tailored on single patient’s needs. Here, we will briefly discuss the recent changes in the clinical management of thyroid nodules, and review the current staging systems of thyroid cancer patients by analyzing promising clinicopathological features (i.e., gender, thyroid auto-immunity, multifocality, PTC histological variants, and vascular invasion) as well as new molecular markers (i.e., BRAF/TERT promoter mutations, miRNAs, and components of the plasminogen activating system) potentially capable of ameliorating the prognosis of PTC patients.

show abstract

Section: Thyroid Cancer Patient’s Stagingmentioning

confidence: 99%

Papillary Thyroid Cancer Prognosis: An Evolving Field

Ulisse

Baldini

Lauro

et al. 2021

Cancers

View full text Add to dashboard Cite

show abstract

“…In meta‐analysis of 906 non‐medullary thyroid carcinomas, PD‐L1 positivity was significantly associated with concurrent thyroiditis with odds ratio (OR) 1.65 [19]. In another meta‐analysis, concurrent chronic lymphocytic thyroiditis was shown to be associated with PD‐L1 positivity with OR 2.19 (p = 0.479) [21] and HR = 1.41 (p = 0.007) [20]. Furthermore, both PD‐L1 and PD‐1 positivity in PTC were shown to correlate with chronic lymphocytic thyroiditis [22].…”

Section: Discussionmentioning

confidence: 99%

“…In systematic reviews and meta-analyses, PD-L1 expression in non-medullary thyroid carcinomas showed significant association with poor survival and recurrence, tumor size, extrathyroidal extension, and unifocality [19,20]. Nevertheless, the comparison of various studies faced the inconsistencies between used antibodies, staining procedures and platforms, as well as scoring methods and cutoffs [19,21].…”

mentioning

confidence: 99%

PD‐L1 and PD‐1 expression in thyroid follicular epithelial dysplasia: Hashimoto thyroiditis related atypia and potential papillary carcinoma precursor

Pakkanen

Kalfeřt

Ahtiainen³

et al. 2022

APMIS

View full text Add to dashboard Cite

Programmed cell death ligand (PD-L1)/PD-1 expression has been studied in a variety of cancers and blockage of PD-L1/PD-1 pathway is a cornerstone of immunotherapy. We studied PD-L1/PD-1 immunohistochemical expression in 47 thyroid gland specimens in groups of (1) Hashimoto thyroiditis (HT) only; (2) HT and follicular epithelial dysplasia (FED); and (3) HT, FED, and papillary thyroid carcinoma (PTC). PD-1 positivity was found in immune cells, namely in lymphocytes, macrophages, and plasma cells with mean values for lymphocytes and macrophages 9% in HT group, 4% in FED group, and 4% in PTC group. PD-L1 positivity was identified in both immune cells and in the normal epithelial cells. In the HT group, mean PD-L1 staining on immune cells was 6%, in FED group 5%, and in PTC group 7%. The mean PD-L1 staining on the epithelial cells in the inflammatory parenchyma was 11.7% in HT, 13.4% in FED, and 8.3% in PTC group. The mean PD-L1 staining of FED foci was 47.2% in FED group and 33.6% in PTC group. The mean tumor proportion score (TPS) was 10.4%, and the mean combined positive score (CPS) was 15.5. At the moment, PTC is not a target of immunotherapy. However, understanding the complex issue of concurrent inflammation and autoimmunity can importantly influence the cancer treatment in future.

show abstract

“…Based on meta-analysis by Wan et al, 28 they found that high expression of PD-L1 in patients with thyroid cancer was associated with poor DFS (disease free survival), tumour size ≥2 cm, tumour recurrence, extrathyroidal extension, concurrent thyroiditis, unifocal tumour, and absence of psammoma bodies. Some of this clinicopathological variables can be also found in our study, such as tumor size and extrathyroidal extension.…”

Section: Discussionmentioning

confidence: 99%

Association of Programmed Death-Ligand 1 Expression with Aggressive Histological Types of Thyroid Carcinoma

Harahap¹,

Lay²,

Kodariah³

et al. 2022

CMAR

View full text Add to dashboard Cite

Introduction Immunohistochemical expression of programmed death-ligand 1 (PD-L1) has become a biomarker to predict the usefulness of cancer immunotherapy using PD-1/PD-L1 blockade in a variety of advanced-stage tumours. This emerging biomarker may serve to generate novel therapies for aggressive thyroid carcinoma (TC), which has not shown optimal results with existing treatments. Methods The present study investigated the relevance of PD-L1 expression in aggressive histological types of TC compared with that found in less aggressive types. Surgically resected specimens were investigated, including 52 cases of TC consisting of 26 cases of aggressive histological types and 26 cases of less aggressive histological types. Immunohistochemical examinations were carried out on paraffin blocks of both groups using a mouse monoclonal primary antibody against PD-L1 (clone 22C3). PD-L1 expression was evaluated by calculating the tumour proportion score (TPS) in both groups. Results The results revealed a significant difference in the median TPS value of PD-L1 expression between the two groups. The TPS values were found to be higher in the group of aggressive histological types of TC compared with those in the group of less aggressive histological types. A significant difference in TPS value was also found for the extrathyroidal extension variable. Discussion In conclusion, the present study found a significant association between PD-L1 expression and the aggressive histological type of TC. In addition, a potential association between PD-L1 expression and the presence of extrathyroidal extension of TC was observed. These findings provide novel approaches for immunotherapy as a potential new treatment modality in patients with aggressive histological types of TC.

show abstract

Association between programmed cell death ligand 1 expression and thyroid cancer

Cited by 12 publications

References 44 publications

Papillary Thyroid Cancer Prognosis: An Evolving Field

Papillary Thyroid Cancer Prognosis: An Evolving Field

PD‐L1 and PD‐1 expression in thyroid follicular epithelial dysplasia: Hashimoto thyroiditis related atypia and potential papillary carcinoma precursor

Association of Programmed Death-Ligand 1 Expression with Aggressive Histological Types of Thyroid Carcinoma

Contact Info

Product

Resources

About